Patritumab deruxtecan (HER3-DXd) is an antibody-drug coupling (ADC) targeting HER3 consisting of a fully humanized anti-HER3 IgG1 monoclonal antibody linked via a cleavable tetrapeptide linker to a topoisomerase I inhibitor payload (an ezetiocan derivative, DXd) for the study of non-small cell lung cancer (NSCLC).
Purity:
95.00%
CAS Number:
[2227102-46-5]
Target:
Antibody-Drug Conjugates (ADCs)
* VAT and and shipping costs not included. Errors and price changes excepted